secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056948
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics Q1 2024: rev $1.4M, net loss $6.5M; new Genentech OpRegen deal
--------------------------------------------------------------------------------

- Revenue of $1.4M, down from $2.4M YoY; net loss attributable $6.5M ($0.04/sh) vs $4.4M ($0.03/sh).
- Cash $43.6M; expected to fund operations into Q3 2025.
- New services agreement with Genentech to support OpRegen clinical and manufacturing activities.
- OpRegen Phase 1/2a long-term data: mean BCVA gain of 5.5 letters at 24 months in Cohort 4 patients.
- OPC1 clinical study start-up underway; received CIRM grant for 2nd Annual SCI Investor Symposium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/0000950170-24-056948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017024056948/lctx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer